1-20 of 27
Nola Hylton
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract OT1-10-02: I-SPY2 endocrine optimization protocol (EOP): A pilot neoadjuvant endocrine therapy study with amcenestrant as monotherapy or in combination with abemacicilib or letrozole in molecularly selected HR+/HER2- clinical stage 2/3 breast cancer

A. Jo Chien, Kevin M Kalinsky, Julissa Molina-Vega, Rita Mukhtar, Karthik Giridhar, Olufunmilayo I Olopade, Amrita Basu, Smita M Asare, Paul Henderson, Gillian Hirst, Ruixiao Lu, Ella Jones, Nola Hylton, Lamorna Brown-Swigart, Laura J van 't Veer, Douglas Yee, Ingrid Mayer, Laura J Esserman
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): OT1-10-02.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-OT1-10-02
Published: 15 February 2022
View article
Journal Articles

Abstract GS4-02: Analysis of clinical outcomes and expression-based immune signatures by race in the I-SPY 2 trial

Beverly Kyalwazi, Christina Yau, Olufunmilayo Olopade, A. Jo Chien, Anne Wallace, Andres Forero-Torres, Lajos Pusztai, Erin Ellis, Kathy Albain, Anne Blaes, Barbara Haley, Judy Boughey, Anthony Elias, Amy Clark, Claudine Isaacs, Rita Nanda, Hyo Han, Rachel Yung, Debu Tripathy, Kristen Edmiston, Rebecca Viscusi, Donald Northfelt, Qamar Khan, Ashish Sanil, Scott Berry, Smita Asare, Amy Wilson, Gillian Hirst, Nola Hylton, Michelle Melisko, Jane Perlmutter, Hope Rugo, Fraser Symmans, Laura van ‘t Veer, Donald Berry, Laura Esserman
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): GS4-02.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-GS4-02
Published: 15 February 2022
View article
Journal Articles

Abstract PD8-07: Evaluation of Tucatinib + (Paclitaxel + Pertuzumab + Trastuzumab) followed by AC in high-risk HER2 positive (HER2+) stage II/III breast cancer: Results from the I-SPY 2 TRIAL

David A Potter, Erin Roesch, Christina Yau, Ruixiao Lu, Denise Wolf, Susan Samson, Debra Stafford, Kathy S Albain, Claudine Isaacs, Meghana Trivedi, Douglas Yee, Judy Boughey, Alexandra Thomas, A. Jo Chien, Nola Hylton, Wen Li, Angela DeMichele, Jane Perlmutter, W. Fraser Symmans, Dawn L Hershman, Michelle Melisko, Laura J van 't Veer, Amy Wilson, Smita M Asare, Donald A Berry, Richard Schwab, Hope S Rugo, Laura J Esserman
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): PD8-07.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-PD8-07
Published: 15 February 2022
View article
Journal Articles

Abstract 2804: Impact of deformable registration methods for prediction of treatment response to neo-adjuvant chemotherapy in breast cancer

Snekha Thakran, Eric Cohen, Nariman Jahani, Susan P. Weinstein, Lauren Pantalone, Nola Hylton, David Newitt, Christos Davatzikos, Despina Kontos
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 2804.
DOI: https://doi.org/10.1158/1538-7445.AM2021-2804
Published: 01 July 2021
View article
Journal Articles

Abstract PD9-04: Identification of biomarkers associated with therapeutic resistance: Quantitative protein/phosphoprotein analysis of ~750 patients across 8 arms of the neoadjuvant I-SPY 2 TRIAL for high-risk early stage breast cancer

Julia Wulfkuhle, Denise Wolf, Christina Yau, Lamorna Brown-Swigart, Rosa I Gallagher, Gillian Hirst, Laura Sit, Smita Asare, I-SPY 2 TRIAL Investigators, Nola Hylton, Angela DeMichele, Douglas Yee, Jo Chien, Hope Rugo, John Park, Kathy Albain, Rita Nanda, Debu Tripathy, Richard Schwab, Don Berry, Laura Esserman, Laura van t' Veer, Emanual Petricoin, III
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): PD9-04.
DOI: https://doi.org/10.1158/1538-7445.SABCS20-PD9-04
Published: 15 February 2021
View article
Journal Articles

Abstract PD6-08: DCE-MRI derived imaging features for characterizing invasive lobular breast cancer and predicting recurrence-free survival after neoadjuvant therapy

Geraldine Tran, Ella Jones, Wen Li, Kelly Fahrner-Scott, David Newitt, Bonnie Joe, Laura Esserman, Nola Hylton, Rita Mukhtar
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): PD6-08.
DOI: https://doi.org/10.1158/1538-7445.SABCS20-PD6-08
Published: 15 February 2021
View article
Journal Articles

Abstract PS11-04: Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatment arms and molecular subtypes

Katharine Yu, Amrita Basu, Christina Yau, Denise Wolf, Gillian Hirst, Laura Sit, Nicholas O’Grady, Thelma Brown, I-SPY 2 TRIAL Investigators, Angela DeMichele, Don Berry, Nola Hylton, Doug Yee, Laura Esserman, Laura van 't Veer, Marina Sirota
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): PS11-04.
DOI: https://doi.org/10.1158/1538-7445.SABCS20-PS11-04
Published: 15 February 2021
View article
Journal Articles

Abstract PD5-01: Magnetic resonance imaging insights from an active surveillance cohort of women with DCIS

Heather Greenwood, Rita Freimanis, Case Brabham, Rita Mukhtar, Gillian Hirst, Paul Kim, April Liang, Laura Esserman, Nola Hylton, Amrita Basu
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): PD5-01.
DOI: https://doi.org/10.1158/1538-7445.SABCS20-PD5-01
Published: 15 February 2021
View article
Journal Articles

Abstract PS1-03: Active surveillance for DCIS: Clinical outcomes at 5.6 years mean follow-up

Case Brabham, Rita Mukhtar, April Liang, Paul Kim, Gillian Hirst, Amrita Basu, Heather Greenwood, Rita Freimanis, Alexander Borowsky, Shelley Hwang, Rick Baehner, Gregor Krings, Nola Hylton, Laura Esserman
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): PS1-03.
DOI: https://doi.org/10.1158/1538-7445.SABCS20-PS1-03
Published: 15 February 2021
View article
Journal Articles

Abstract CT011: Evaluation of durvalumab in combination with olaparib and paclitaxel in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL

Lajos Pusztai, Hyo S. Han, Christina Yau, Denise Wolf, Anne M. Wallace, Rebecca Shatsky, Teresa Helsten, Judy C. Boughey, Tufia Haddad, Erica Stringer-Reasor, Carla Falkson, A. Jo Chien, Rita Mukhtar, Anthony Elias, Borges Virginia, Rita Nanda, Douglas Yee, Kevin Kalinsky, Kathy S. Albain, Aixa Soyano Muller, Kathleen Kemmer, Amy S. Clark, Claudine Isaacs, Alexandra Thomas, Nola Hylton, W. Fraser Symmans, Jane Perlmutter, Michelle Melisko, Hope S. Rugo, Richard Schwab, Amy Wilson, Amy Wilson, Ruby Singhrao, Smita Asare, Laura J. van't Veer, Angela M. DeMichele, Ashish Sanil, Donald A. Berry, Laura J. Esserman, Trial Consortium I-SPY 2
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): CT011.
DOI: https://doi.org/10.1158/1538-7445.AM2020-CT011
Published: 15 August 2020
View article
Journal Articles

Abstract PD9-08: Accuracy of ultrasound in evaluating response to neoadjuvant therapy in invasive lobular carcinoma of the breast

Kelly Fahrner-Scott, Jasmine M Wong, Merisa Piper, Cheryl Ewing, Michael Alvarado, Laura J Esserman, Nola Hylton, Rita A Mukhtar, MD
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): PD9-08.
DOI: https://doi.org/10.1158/1538-7445.SABCS19-PD9-08
Published: 15 February 2020
View article
Journal Articles

Abstract PD9-06: Additive benefit of MRI background parenchymal enhancement (BPE) to an MRI tumor volume model for predicting pathologic complete response (pCR) to neoadjuvant treatment in ISPY2

Vignesh A. Arasu, Paul Kim, Wen Li, Fredrik Strand, Cody McHargue, Ella Jones, David Newitt, John Kornak, Laura Esserman, Nola Hylton, ACRIN 6657 Trial TeamI-SPY Investigators Network
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): PD9-06.
DOI: https://doi.org/10.1158/1538-7445.SABCS19-PD9-06
Published: 15 February 2020
View article
Journal Articles

Abstract P6-10-06: Amsterdam 70-gene profile (MammaPrint) low risk, even in the HER2 positive subset, identifies a population of women with lower early risk for recurrence despite low response rates to chemotherapy and to HER2 targeted therapy

Paula R Pohlmann, Christina Yau, Angela DeMichele, Claudine Isaacs, Judy C Boughey, Nola Hylton, Michelle E Melisko, Jane Perlmutter, Hope S Rugo, W. Fraser Symmans, I-SPY 2 TRIAL Consortium, Donald A Berry, Laura Esserman
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): P6-10-06.
DOI: https://doi.org/10.1158/1538-7445.SABCS19-P6-10-06
Published: 15 February 2020
View article
Journal Articles

Abstract 3361: A prescription for new trial designs for drug development focused on the neoadjuvant setting: Save lives, resources, and time

Andreas Karlsson, Yiwey Shieh, Andre Dempsey, Christina Yau, Angela Dmichele, Doug Yes, Laura van't Veer, Nola Hylton, Martin Eklund, Laura Esserman
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 3361.
DOI: https://doi.org/10.1158/1538-7445.AM2019-3361
Published: 01 July 2019
View article
Journal Articles

Abstract CT136: Evaluation of talazoparib in combination with irinotecan in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL

Richard Schwab, Amy S. Clark, Christina Yau, Nola Hylton, Wen Li, Denise Wolfe, A Jo Chien, Anne M. Wallace, Andres Forero-Torres, Erica Stringer-Reasor, Rita Nanda, Nora Jaskowiak, Judy Boughey, Tufia Haddad, Heather S. Han, Catherine Lee, Kathy Albain, Claudine Isaacs, Anthony D. Elias, Erin D. Ellis, Payal Shah, Julie E. Lang, Janice Lu, Debasish Tripathy, Kathleen Kemmer, Douglas Yee, Barbara Haley, Melanie Majure, Erin Roesch, Christos Vaklavas, Cheryl Ewing, Teresa Helsten, W Fraser Symmans, Jane Perlmutter, Hope S. Rugo, Michelle Melisko, Amy Wilson, Ruby Singhrao, Laura van 't Veer, Angela DeMichele, Smita Asare, Don Berry, Laura J. Esserman
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): CT136.
DOI: https://doi.org/10.1158/1538-7445.AM2019-CT136
Published: 01 July 2019
View article
Journal Articles

Predicting Responses to Neoadjuvant Chemotherapy in Breast Cancer: ACRIN 6691 Trial of Diffuse Optical Spectroscopic Imaging

Bruce J. Tromberg, Zheng Zhang, Anaïs Leproux, Thomas D. O'Sullivan, Albert E. Cerussi, Philip M. Carpenter, Rita S. Mehta, Darren Roblyer, Wei Yang, Keith D. Paulsen, Brian W. Pogue, Shudong Jiang, Peter A. Kaufman, Arjun G. Yodh, So Hyun Chung, Mitchell Schnall, Bradley S. Snyder, Nola Hylton, David A. Boas, Stefan A. Carp, Steven J. Isakoff, David Mankoff
Journal: Cancer Research
Cancer Res (2016) 76 (20): 5933–5944.
DOI: https://doi.org/10.1158/0008-5472.CAN-16-0346
Published: 13 October 2016
View article
PDF
Includes: Supplementary data
Journal Articles

Abstract CT106: Efficacy of pertuzumab/trastuzumab/paclitaxel over standard trastuzumab/paclitaxel therapy for HER2+ breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL

Meredith Buxton, Angela M. DeMichele, Stephen Chia, Laura van't Veer, Jo Chien, Anne Wallace, Henry Kaplan, Julie Lang, Douglas Yee, Claudine Isaacs, Stacy Moulder, Kathy Albain, Judy Boughey, Kathleen Kemmer, Barbara Haley, Susan Minton, Andres Forero, Rita Nanda, Anthony Elias, Larissa Korde, Rebecca Viscuzi, Hope Rugo, Richard Schwab, Fraser Symmans, Melissa Paoloni, Nola Hylton, Michael Hogarth, Julia Lyandres, Jane Perlmutter, Ashish Sanil, Christina Yau, Laura Esserman, Don Berry, I-SPY 2 TRIAL Investigators
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): CT106.
DOI: https://doi.org/10.1158/1538-7445.AM2016-CT106
Published: 15 July 2016
View article
Journal Articles

Abstract CT042: Efficacy of T-DM1+pertuzumab over standard therapy for HER2+ breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL

Angela M. DeMichele, Stacy Moulder, Meredith Buxton, Douglas Yee, Anne Wallace, Jo Chien, Claudine Isaacs, Kathy Albain, Judy Boughey, Kathleen Kemmer, Barbara Haley, Julie Lang, Henry Kaplan, Susan Minton, Andres Forero, Anthony Elias, Rita Nanda, Larissa Korde, Richard Schwab, Michelle Melisko, Ashish Sanil, Michael Hogarth, Nola Hylton, Melissa Paoloni, Fraser Symmans, Jane Perlmutter, Julia Lyandres, Christina Yau, Don Berry, Laura Esserman, I-SPY 2 TRIAL Investigators
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): CT042.
DOI: https://doi.org/10.1158/1538-7445.AM2016-CT042
Published: 15 July 2016
View article
Journal Articles

Abstract P3-06-05: Evaluation of an in vitro derived signature of olaparib response (PARPi-7) as a predictive biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 TRIAL

Denise M Wolf, Christina Yau, Ashish Sanil, Anneleen Daemen, Laura Heiser, Joe Gray, Lamorna Brown-Swigart, Susan Flynn, Gillian Hirst, I-SPY 2 TRIAL Investigators, Meredith Buxton, Angela DeMichele, Nola Hylton, Fraser Symmans, Doug Yee, Melissa Paoloni, Laura Esserman, Don Berry, Hope Rugo, Olufunmilayo Olopade, Laura van 't Veer
Journal: Cancer Research
Cancer Res (2015) 75 (9_Supplement): P3-06-05.
DOI: https://doi.org/10.1158/1538-7445.SABCS14-P3-06-05
Published: 01 May 2015
View article
Journal Articles

Abstract P3-06-29: MammaPrint High1/High2 risk class as a biomarker of response to neratinib plus standard neoadjuvant therapy for breast cancer in the I-SPY 2 TRIAL

Christina Yau, Denise M Wolf, Ashish Sanil, Jo Chien, Anne Wallace, Judy Boughey, Doug Yee, Debu Tripathy, Angela DeMichele, Rita Nanda, Steven Chiu, Claudine Isaacs, Kathy Albain, Hank Kaplan, Stacey Moulder, Rebecca Viscusi, Donald Northfelt, Kirsten Edmiston, Anthony Elias, Toncred Styblo, Barbara Haley, Lamorna Brown-Swigart, Susan Flynn, Gillian L Hirst, Meredith Buxton, Nola Hylton, Melissa Paoloni, W Fraser Symmans, Laura Esserman, Don Berry, Minetta C Liu, John W Park, Laura van 't Veer
Journal: Cancer Research
Cancer Res (2015) 75 (9_Supplement): P3-06-29.
DOI: https://doi.org/10.1158/1538-7445.SABCS14-P3-06-29
Published: 01 May 2015
View article